Email this article 
Post‑COVID‑19 Syndrome Mechanisms, Prevention and Management
Abstract
Keywords
Full Text:
PDFReferences
Baud D, Qi X, Nielsen‑Saines K, Musso D, Pomar L, Favre G.
Real estimates of mortality following COVID‑19 infection.
Lancet Infect Dis 2020;20:773.
Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, et al. A review of persistent post‑COVID
syndrome (PPCS). Clin Rev Allergy Immunol 2021:1‑9. doi:
1007/s12016‑021‑08848‑3.
Garg M, Maralakunte M, Garg S, Dhooria S, Sehgal I, Bhalla AS,
et al. The conundrum of ‘long‑COVID‑19ʹ: A narrative review.
Int J Gen Med 2021;14:2491‑506.
Carroll E, Neumann H, Aguero-Rosenfeld ME, Lighter J,
Czeisler BM, Melmed K, et al. Post–COVID-19 inflammatory
syndrome manifesting as refractory status epilepticus. Epilepsia
;61:e135‑e9.
Carfì A, Bernabei R, Landi F. Persistent symptoms in patients
after acute COVID‑19. JAMA 2020;324:603‑5.
Tenforde MW, Kim SS, Lindsell CJ, Rose EB, Shapiro NI,
Files DC, et al. Symptom duration and risk factors for delayed
return to usual health among outpatients with COVID‑19
in a multistate health care systems network—United States,
March–June 2020. MMWR Morb Mortal Wkly 2020;69:993‑8.
Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6‑month
consequences of COVID‑19 in patients discharged from hospital:
A cohort study. Lancet 2021;397:220‑32.
Greenhalgh T, Knight M, Buxton M, Husain L. Management of
post‑acute COVID‑19 in primary care. BMJ 2020;370:m3026.
doi: 10.1136/bmj.m3026.
Nabavi N. Long COVID: How to define it and how to manage it.
BMJ 2020;370:m3489. doi: 10.1136/bmj.m3489.
Garg P, Arora U, Kumar A, Wig N. The “post-COVID” syndrome:
How deep is the damage? J Med Virol 2021;93:673‑74.
Shah W, Hillman T, Playford ED, Hishmeh L. Managing the
long term effects of COVID‑19: Summary of NICE, SIGN, and
RCGP rapid guideline. BMJ 2021;372:n136. doi: 10.1136/bmj.
n136.
Lopez‑Leon S, Wegman‑Ostrosky T, Perelman C, Sepulveda R,
Rebolledo PA, Cuapio A, et al. More than 50 Long‑term effects
of COVID‑19: A systematic review and meta‑analysis. SSRN J
Available from: https://ssrn.com/abstract=3769978.
Lee SH, Shin H‑S, Park HY, Kim JL, Lee JJ, Lee H, et al.
Depression as a mediator of chronic fatigue and post‑traumatic
stress symptoms in Middle East respiratory syndrome survivors.
Psychiatry investig 2019;16:59‑64.
Lam MH‑B, Wing Y‑K, Yu MW‑M, Leung C‑M, Ma RC,
Kong AP, et al. Mental morbidities and chronic fatigue in severe
acute respiratory syndrome survivors: Long‑term follow‑up. Arch
Intern Med 2009;169:2142‑7.
Cellai M, O’Keefe JB, editors. Characterization of prolonged
COVID‑19 symptoms in an outpatient telemedicine clinic. Open
Forum Infectious Diseases: Oxford University Press US; 2020.
Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS,
Bowyer RC, et al. Attributes and predictors of long COVID. Nat
Med 2021;27:626‑31.
Cirulli E, Barrett KMS, Riffle S, Bolze A, Neveux I, Dabe S,
et al. Long‑term COVID‑19 symptoms in a large unselected
population. medrxiv 2020. doi: 10.1101/2020.10.07.20208702.
Bliddal S, Banasik K, Pedersen OB, Nissen J, Cantwell L,
Schwinn M, et al. Acute and persistent symptoms in
non‑hospitalized PCR‑confirmed COVID‑19 patients. Sci Rep
;11:1‑11. doi: 10.1038/s41598‑021‑92045‑x.
Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P,
Hober S, et al. Symptoms and functional impairment assessed
months after mild COVID‑19 among health care workers.
JAMA 2021;325:2015‑6.
Nehme M, Braillard O, Alcoba G, Aebischer Perone S,
Courvoisier D, Chappuis F, et al. COVID‑19 symptoms:
Longitudinal evolution and persistence in outpatient settings.
Ann Intern Med 2021;174:723‑5.
Moreno‑Pérez O, Merino E, Leon‑Ramirez J‑M, Andres M,
Ramos JM, Arenas‑Jiménez J, et al. Post‑acute COVID‑19
syndrome. Incidence and risk factors: A Mediterranean cohort
study. J Infect 2021;82:378‑83.
Venturelli S, Benatti SV, Casati M, Binda F, Zuglian G, Imeri G,
et al. Surviving COVID‑19 in Bergamo province: A post‑acute
outpatient re‑evaluation. Epidemiol Infect 2021;149:e32. doi:
1017/S0950268821000145.
Chiesa-Estomba CM, Lechien JR, Radulesco T, Michel J,
Sowerby LJ, Hopkins C, et al. Patterns of smell recovery in
patients affected by the COVID-19 outbreak. Eur J Neurol
;27:2318‑21.
Ayoubkhani D. Prevalence of ongoing symptoms following
coronavirus (COVID‑19) infection in the UK: 1 April 2021. Off
Natl Stat 2021:1‑16.
Morin L, Savale L, Pham T, Colle R, Figueiredo S, Harrois A,
et al. Four‑month clinical status of a cohort of patients after
hospitalization for COVID‑19. JAMA 2021;325:1525‑34.
Ghosn J, Piroth L, Epaulard O, Le Turnier P, Mentré F,
Bachelet D, et al. Persistent COVID‑19 symptoms are highly
prevalent 6 months after hospitalization: Results from a large
prospective cohort. Clin Microbiol Infect 2021:1041.e1‑1041.e4.
doi: 10.1016/j.cmi. 2021.03.012.
Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L,
Gruell H, et al. Post‑COVID syndrome in non‑hospitalised
patients with COVID‑19: A longitudinal prospective cohort
study. Lancet Reg Health Eur 2021;6:100122. doi: 10.1016/j.
lanepe. 2021.100122.
Whitaker M, Elliott J, Chadeau‑Hyam M, Riley S, Darzi A,
Cooke G, et al. Persistent symptoms following SARS‑CoV‑2
infection in a random community sample of 508,707 people.
medRxiv 2021. doi: 10.1101/2021.06.28.21259452.
Thompson EJ, Williams DM, Walker AJ, Mitchell RE,
Niedzwiedz CL, Yang TC, et al. Risk factors for long COVID:
Analyses of 10 longitudinal studies and electronic health records
in the UK. medRxiv 2021. doi: 10.1101/2021.06.24.21259277.
Inoue S, Hatakeyama J, Kondo Y, Hifumi T, Sakuramoto H,
Kawasaki T, et al. Post-intensive care syndrome: Its
pathophysiology, prevention, and future directions. Acute Med
Surg 2019;6:233‑46.
Ehrenfeld M, Tincani A, Andreoli L, Cattalini M, Greenbaum A,
Kanduc D, et al. COVID‑19 and autoimmunity. Autoimmun Rev
;19:102597. doi: 10.1016/j.autrev. 2020.102597.
Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, et al. Clinical
characteristics of severe acute respiratory syndrome coronavirus
reactivation. J Infect 2020;80:e14‑e7.
Centers for Diseases Control and Prevention. Investigative criteria
for suspected cases of SARS‑CoV‑2 reinfection (ICR). 2020.
Available from: https://www.cdc.gov/coronavirus/2019‑ncov/php/
invest‑criteria.html.
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C,
Stevens JS, et al. Post‑acute COVID‑19 syndrome. Nat Med
;27:601‑15.
Stratton CW, Tang YW, Lu H. Pathogenesis-directed therapy of
novel coronavirus disease. J Med Virol 2021;93:1320‑42.
Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of
angiotensin‑converting enzyme 2 (ACE2) in COVID‑19. Crit
Care 2020;24:1‑10. doi: 10.1186/s13054‑020‑03120‑0.
Afrin LB, Weinstock LB, Molderings GJ. COVID‑19
hyperinflammation and post‑COVID‑19 illness may be rooted in
mast cell activation syndrome. Int J Infect Dis 2020;100:327‑32.
Michelen M, Cheng V, Manoharan L, Elkheir N, Dagens D, Hastie C, et al. Characterising long term COVID‑19:
A living systematic review. MedRxiv 2021. doi:
1101/2020.12.08.20246025.
Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C,
Chandan JS, et al. Symptoms, complications and management of
long COVID: A review. J R Soc Med 2021;114:428‑42.
Lombardo MDM, Foppiani A, Peretti GM, Mangiavini L,
Battezzati A, Bertoli S, et al. Long‑term coronavirus disease
complications in inpatients and outpatients: A one‑year
follow‑up cohort study. Open Forum Infect Dis 2021;8:ofab384.
doi: 10.1093/ofid/ofab384.
Ngai JC, Ko FW, Ng SS, TO KW, Tong M, Hui DS. The
long-term impact of severe acute respiratory syndrome on
pulmonary function, exercise capacity and health status.
Respirology 2010;15:543‑50.
Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y,
et al. Characterizing long COVID in an international cohort:
months of symptoms and their impact. SSRN J 2021. Available
from: https://ssrn.com/abstract=3820561.
Simani L, Ramezani M, Darazam IA, Sagharichi M,
Aalipour MA, Ghorbani F, et al. Prevalence and correlates of
chronic fatigue syndrome and post‑traumatic stress disorder after
the outbreak of the COVID‑19. J Neurovirol 2021;27:154‑9.
Garg M, Prabhakar N, Bhalla AS, Irodi A, Sehgal I, Debi U,
et al. Computed tomography chest in COVID‑19: When & why?
Indian J Med Res 2021;153:86‑92.
Froidure A, Mahsouli A, Liistro G, De Greef J, Belkhir L,
Gerard L, et al. Integrative respiratory follow‑up of severe
COVID‑19 reveals common functional and lung imaging
sequelae. Respir Med 2021;181:106383. doi: 10.1016/j.rmed.
106383.
Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A,
Gouze H, et al. Post‑discharge persistent symptoms and
health‑related quality of life after hospitalization for COVID‑19.
J Infect 2020;81:e4‑e6.
Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical
sequelae of COVID‑19 survivors in Wuhan, China:
A single‑centre longitudinal study. Clin Microbiol Infect
;27:89‑95.
Frija‑Masson J, Debray MP, Gilbert M, Lescure FX, Travert F,
Borie R, et al. Functional characteristics of patients with
SARS‑CoV‑2 pneumonia at 30 days post‑infection. Eur Respir J
;56:2001754. doi: 10.1183/13993003.01754‑2020.
Chopra V, Flanders SA, O’Malley M, Malani AN, Prescott HC.
Sixty‑day outcomes among patients hospitalized with COVID‑19.
Ann Intern Med 2021;174:576‑8.
Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O,
McLean L, et al. Postdischarge symptoms and rehabilitation
needs in survivors of COVID‑19 infection: A cross‑sectional
evaluation. J Med Virol 2021;93:1013‑22.
Lund LC, Hallas J, Nielsen H, Koch A, Mogensen SH, Brun NC,
et al. Post‑acute effects of SARS‑CoV‑2 infection in individuals
not requiring hospital admission: A Danish population‑based
cohort study. Lancet Infect Dis 2021;21:1373‑82.
Darcis G, Bouquegneau A, Maes N, Thys M, Henket M,
Labye F, et al. Long‑term clinical follow‑up of patients suffering
from moderate‑to‑severe COVID‑19 infection: A monocentric
prospective observational cohort study. Int J Infect Dis
;109:209‑16.
Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al. Six‑month
follow‑up chest CT findings after severe COVID‑19 pneumonia.
Radiology 2021;299:E177‑86.
Sonnweber T, Sahanic S, Pizzini A, Luger A, Schwabl C,
Sonnweber B, et al. Cardiopulmonary recovery after COVID‑19:
An observational prospective multicentre trial. Eur Respir J
;57:2003481. doi: 10.1183/13993003.03481‑2020.
Alharthy A, Abuhamdah M, Balhamar A, Faqihi F, Nasim N,
Ahmad S, et al. Residual lung injury in patients recovering
from COVID‑19 critical illness: A prospective longitudinal
point‑of‑care lung ultrasound study. J Ultrasound Med
;40:1823‑38.
Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF,
et al. Follow‑up study of the pulmonary function and related
physiological characteristics of COVID‑19 survivors three
months after recovery. EClinicalMedicine 2020;25:100463. doi:
1016/j.eclinm. 2020.100463.
Tabatabaei SMH, Rajebi H, Moghaddas F, Ghasemiadl M,
Talari H. Chest CT in COVID‑19 pneumonia: What are the
findings in mid‑term follow‑up? Emerg Radiol 2020;27:711‑9.
Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, et al.
Abnormal pulmonary function in COVID‑19 patients at time
of hospital discharge. Eur Respir J 2020;55:2001217. doi:
1183/13993003.01217‑2020.
Huppert LA, Matthay MA, Ware LB, editors. Pathogenesis of
acute respiratory distress syndrome. Seminars in Respiratory and
Critical Ccare Medicine. Thieme Medical Publishers; 2019.
Sidarta‑Oliveira D, Jara CP, Ferruzzi AJ, Skaf MS, Velander WH,
Araujo EP, et al. SARS‑CoV‑2 receptor is co‑expressed
with elements of the kinin–kallikrein, renin–angiotensin and
coagulation systems in alveolar cells. Sci Rep 2020;10:1‑19. doi:
1038/s41598‑020‑76488‑2.
Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A,
Zerbi P, et al. Pulmonary post‑mortem findings in a series of
COVID‑19 cases from northern Italy: A two‑centre descriptive
study. Lancet Infect Dis 2020;20:1135‑40.
Schaller T, Hirschbühl K, Burkhardt K, Braun G, Trepel M,
Märkl B, et al. Postmortem examination of patients with
COVID‑19. JAMA 2020;323:2518‑20.
De Michele S, Sun Y, Yilmaz MM, Katsyv I, Salvatore M,
Dzierba AL, et al. Forty postmortem examinations in
COVID‑19 patients: Two distinct pathologic phenotypes and
correlation with clinical and radiologic findings. Am J Clin
Pathol 2020;154:748‑60.
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical
and immunological features of severe and moderate coronavirus
disease 2019. J Clin Invest 2020;130:2620‑9.
Bharat A, Querrey M, Markov NS, Kim S, Kurihara C,
Garza‑Castillon R, et al. Lung transplantation for patients with
severe COVID‑19. Sci Transl Med 2020;12.
Ramadan MS, Bertolino L, Zampino R, Durante‑Mangoni E,
Monaldi Hospital Cardiovascular Infection Study Group. Cardiac
sequelae after coronavirus disease 2019 recovery: A systematic
review. Clin Microbiol Infect 2021;27:1250‑61.
Moulson N, Petek BJ, Drezner JA, Harmon KG, Kliethermes SA,
Patel MR, et al. SARS‑CoV‑2 cardiac involvement in young
competitive athletes. Circulation 2021;144:256‑66.
Johansson M, Ståhlberg M, Runold M, Nygren‑Bonnier M,
Nilsson J, Olshansky B, et al. Long‑haul post–COVID‑19
symptoms presenting as a variant of postural orthostatic
tachycardia syndrome: The Swedish experience. JACC Case Rep
;3:573‑80.
Miglis MG, Prieto T, Shaik R, Muppidi S, Sinn D‑I, Jaradeh S.
A case report of postural tachycardia syndrome after COVID‑19.
Clin Auton Res 2020;30:449‑51.
Ståhlberg M, Reistam U, Fedorowski A, Villacorta H,
Horiuchi Y, Bax J, et al. Post‑COVID‑19 Tachycardia syndrome: A distinct phenotype of post‑acute COVID‑19 syndrome. Am J
Med 2021;134:1451‑6.
Martinez MW, Tucker AM, Bloom OJ, Green G, DiFiori JP,
Solomon G, et al. Prevalence of inflammatory heart disease
among professional athletes with prior COVID‑19 infection
who received systematic return‑to‑play cardiac screening. JAMA
Cardiol 2021;6:745‑52.
Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K,
Thornton G, et al. Patterns of myocardial injury in recovered
troponin‑positive COVID‑19 patients assessed by cardiovascular
magnetic resonance. Eur Heart J 2021;42:1866‑78.
Al‑Aly Z, Xie Y, Bowe B. High‑dimensional characterization of
post‑acute sequelae of COVID‑19. Nature 2021;594:259‑64.
Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B,
Diamond I, et al. Post‑COVID syndrome in individuals admitted
to hospital with COVID‑19: Retrospective cohort study. BMJ
;372:n693. doi: 10.1136/bmj.n693.
Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C,
Meissner K, et al. Association of cardiac infection with
SARS‑CoV‑2 in confirmed COVID‑19 autopsy cases. JAMA
Cardiol 2020;5:1281‑5.
Siripanthong B, Nazarian S, Muser D, Deo R, Santangeli P,
Khanji MY, et al. Recognizing COVID‑19–related myocarditis:
The possible pathophysiology and proposed guideline for
diagnosis and management. Heart Rhythm 2020;17:1463‑71.
Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. Altered
lipid metabolism in recovered SARS patients twelve
years after infection. Sci Rep 2017;7:1‑12. doi: 10.1038/
s41598‑017‑09536‑z.
Lazzerini PE, Laghi‑Pasini F, Boutjdir M, Capecchi PL.
Cardioimmunology of arrhythmias: The role of autoimmune
and inflammatory cardiac channelopathies. Nat Rev Immunol
;19:63‑4.
Roberts LN, Whyte MB, Georgiou L, Giron G, Czuprynska J,
Rea C, et al. Postdischarge venous thromboembolism following
hospital admission with COVID‑19. Blood 2020;136:1347‑50.
Patell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird WC,
et al. Postdischarge thrombosis and hemorrhage in patients with
COVID‑19. Blood 2020;136:1342‑6.
Salisbury R, Iotchkova V, Jaafar S, Morton J, Sangha G, Shah A,
et al. Incidence of symptomatic, image‑confirmed venous
thromboembolism following hospitalization for COVID‑19 with
‑day follow‑up. Blood Adv 2020;4:6230‑9.
Giannis D, Allen SL, Tsang J, Flint S, Pinhasov T, Williams S,
et al. Postdischarge thromboembolic outcomes and mortality of
hospitalized patients with COVID‑19: The CORE‑19 registry.
Blood 2021;137:2838‑47.
Nicolai L, Leunig A, Brambs S, Kaiser R, Weinberger T,
Weigand M, et al. Immunothrombotic dysregulation in
COVID‑19 pneumonia is associated with respiratory failure and
coagulopathy. Circulation 2020;142:1176‑89.
Pons S, Fodil S, Azoulay E, Zafrani L. The vascular
endothelium: The cornerstone of organ dysfunction in severe
SARS‑CoV‑2 infection. Crit Care 2020;24:1‑8. doi: 10.1186/
s13054‑020‑03062‑7.
Ghebrehiwet B, Peerschke EI. Complement and coagulation:
Key triggers of COVID‑19–induced multiorgan pathology. J Clin
Invest 2020;130:5674‑6.
Hottz ED, Azevedo‑Quintanilha IG, Palhinha L, Teixeira L,
Barreto EA, Pão CR, et al. Platelet activation and
platelet‑monocyte aggregate formation trigger tissue factor
expression in patients with severe COVID‑19. Blood
;136:1330‑41.
Szturmowicz M, Demkow U. Neutrophil extracellular
traps (NETs) in severe SARS‑CoV‑2 lung disease. Int J Mol Sci
;22:8854. doi: 10.3390/ijms22168854.
Song W‑C, FitzGerald GA. COVID‑19, microangiopathy,
hemostatic activation, and complement. J Clin Invest
;130:3950‑3.
Bowe B, Xie Y, Xu E, Al‑Aly Z. Kidney outcomes in long
COVID. J Am Soc Nephrol 2021;32:2851‑62.
Robbins‑Juarez SY, Qian L, King KL, Stevens JS, Husain SA,
Radhakrishnan J, et al. Outcomes for patients with COVID‑19
and acute kidney injury: A systematic review and meta‑analysis.
Kidney Int Rep 2020;5:1149‑60.
Cummings MJ, Baldwin MR, Abrams D, Jacobson SD,
Meyer BJ, Balough EM, et al. Epidemiology, clinical
course, and outcomes of critically ill adults with COVID‑19
in New York City: A prospective cohort study. Lancet
;395:1763‑70.
Stevens JS, King KL, Robbins‑Juarez SY, Khairallah P, Toma K,
Alvarado Verduzco H, et al. High rate of renal recovery in
survivors of COVID‑19 associated acute renal failure requiring
renal replacement therapy. PLoS One 2020;15:e0244131. doi:
1371/journal.pone. 0244131.
Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL,
et al. Acute kidney injury in patients hospitalized with
COVID‑19. Kidney Int 2020;98:209‑18.
Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, et al. Renal
involvement and early prognosis in patients with COVID‑19
pneumonia. J Am Soc Nephrol 2020;31:1157‑65.
Stockmann H, Hardenberg J‑HB, Aigner A, Hinze C, Gotthardt I,
Stier B, et al. High rates of long‑term renal recovery in
survivors of coronavirus disease 2019–associated acute kidney
injury requiring kidney replacement therapy. Kidney Int
;99:1021‑2.
Su H, Yang M, Wan C, Yi L‑X, Tang F, Zhu H‑Y, et al. Renal
histopathological analysis of 26 postmortem findings of patients
with COVID‑19 in China. Kidney Int 2020;98:219‑27.
Kudose S, Batal I, Santoriello D, Xu K, Barasch J, Peleg Y, et al.
Kidney biopsy findings in patients with COVID‑19. J Am Soc
Nephrol 2020;31:1959‑68.
Sharma P, Uppal NN, Wanchoo R, Shah HH, Yang Y, Parikh R,
et al. COVID‑19–associated kidney injury: A case series of
kidney biopsy findings. J Am Soc Nephrol 2020;31:1948‑58.
Golmai P, Larsen CP, DeVita MV, Wahl SJ, Weins A,
Rennke HG, et al. Histopathologic and ultrastructural findings in
postmortem kidney biopsy material in 12 patients with AKI and
COVID‑19. J Am Soc Nephrol 2020;31:1944‑7.
Santoriello D, Khairallah P, Bomback AS, Xu K, Kudose S,
Batal I, et al. Postmortem kidney pathology findings in patients
with COVID‑19. J Am Soc Nephrol 2020;31:2158‑67.
Velez JCQ, Caza T, Larsen CP. COVAN is the new HIVAN: The
re‑emergence of collapsing glomerulopathy with COVID‑19. Nat
Rev Nephrol 2020;16:565‑7.
Peleg Y, Kudose S, D’Agati V, Siddall E, Ahmad S, Nickolas T,
et al. Acute kidney injury due to collapsing glomerulopathy
following COVID‑19 infection. Kidney Int Rep 2020;5:940‑5.
Jhaveri KD, Meir LR, Chang BSF, Parikh R, Wanchoo R,
Barilla‑LaBarca ML, et al. Thrombotic microangiopathy in a
patient with COVID‑19. Kidney Int 2020;98:509‑12.
Sathish T, Cao Y, Kapoor N. Newly diagnosed diabetes in
COVID‑19 patients. Prim Care Diabetes 2020;15:194.
Akter F, Mannan A, Mehedi HH, Rob MA, Ahmed S,
Salauddin A, et al. Clinical characteristics and short term
outcomes after recovery from COVID‑19 in patients with and without diabetes in Bangladesh. Diabetes Metab Syndr
;14:2031‑8.
Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and
characterisation of post-COVID-19 manifestations. Int J Clin
Pract 2021;75:e13746. doi: 10.1111/ijcp. 13746.
Ghosh A, Anjana RM, Rani CSS, Rani SJ, Gupta R, Jha A, et al.
Glycemic parameters in patients with new‑onset diabetes during
COVID‑19 pandemic are more severe than in patients with
new‑onset diabetes before the pandemic: NOD COVID India
Study. Diabetes Metab Syndr 2021;15:215‑20.
Yuan K, Gong Y‑M, Liu L, Sun Y‑K, Tian S‑S, Wang Y‑J, et al.
Prevalence of posttraumatic stress disorder after infectious
disease pandemics in the twenty‑first century, including
COVID‑19: A meta‑analysis and systematic review. Mol
Psychiatry 2021;26:4982‑4998.
Ruggeri RM, Campennì A, Siracusa M, Frazzetto G, Gullo D.
Subacute thyroiditis in a patient infected with SARS‑COV‑2:
An endocrine complication linked to the COVID‑19 pandemic.
Hormones 2021;20:219‑21.
Brancatella A, Ricci D, Viola N, Sgrò D, Santini F, Latrofa F.
Subacute thyroiditis after Sars‑COV‑2 infection. J Clin
Endocrinol Metab 2020;105:2367‑70.
Moreno-Perez O, Merino E, Alfayate R, Torregrosa ME,
Andres M, Leon-Ramirez JM, et al. Male pituitary-gonadal axis
dysfunction in post-acute COVID-19 syndrome. Prevalence and
associated factors: A Mediterranean case series. Clin Endocrinol
doi: 10.1111/cen. 14537.
Mondal S, DasGupta R, Lodh M, Gorai R, Choudhury B,
Hazra AK, et al. Predictors of new‑onset diabetic ketoacidosis in
patients with moderate to severe COVID‑19 receiving parenteral
glucocorticoids: A prospective single‑centre study among Indian
type 2 diabetes patients. Diabetes Metab Syndr 2021;15:795‑801.
Gentile S, Strollo F, Mambro A, Ceriello A. COVID‑19,
ketoacidosis and new‑onset diabetes: Are there possible cause
and effect relationships among them? Diabetes Obes Metab
;22:2507‑8.
Yang J‑K, Lin S‑S, Ji X‑J, Guo L‑M. Binding of SARS
coronavirus to its receptor damages islets and causes acute
diabetes. Acta Diabetol 2010;47:193‑9.
Farag AA, Hassanin HM, Soliman HH, Sallam A, Sediq AM,
Elbanna K. Newly diagnosed diabetes in patients with
COVID‑19: Different types and short‑term outcomes. Trop Med
Infect Dis 2021;6:142. doi: 10.3390/tropicalmed6030142.
Baig AM. Deleterious outcomes in long‑hauler COVID‑19:
The effects of SARS‑CoV‑2 on the CNS in chronic COVID
syndrome. ACS Chem Neurosci 2020;11:4017‑20.
Wijeratne T, Crewther S. Post‑COVID 19 Neurological
Syndrome (PCNS); a novel syndrome with challenges for
the global neurology community. J Neurol Sci 2020;419. doi:
1016/j.jns. 2020.117179
Boscolo‑Rizzo P, Borsetto D, Fabbris C, Spinato G, Frezza D,
Menegaldo A, et al. Evolution of altered sense of smell or
taste in patients with mildly symptomatic COVID‑19. JAMA
Otolaryngol Head Neck Surg 2020;146:729‑32.
Lu Y, Li X, Geng D, Mei N, Wu P‑Y, Huang C‑C, et al. Cerebral
micro‑structural changes in COVID‑19 patients–an MRI‑based
‑month follow‑up study. EClinicalMedicine 2020;25:100484.
Siow I, Lee KS, Zhang JJ, Saffari SE, Ng A, Young B. Stroke
as a neurological complication of COVID‑19: A systematic
review and meta‑analysis of incidence, outcomes and predictors.
J Stroke Cerebrovasc Dis 2021;30:105549. doi: 10.1016/j.
jstrokecerebrovasdis. 2020.105549.
Hernández‑Fernández F, Sandoval Valencia H,
Barbella‑Aponte RA, Collado‑Jiménez R, Ayo‑Martín Ó,
Barrena C, et al. Cerebrovascular disease in patients with
COVID‑19: Neuroimaging, histological and clinical description.
Brain 2020;143:3089‑103.
Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional
associations between COVID‑19 and psychiatric disorder:
Retrospective cohort studies of 62 354 COVID‑19 cases in the
USA. Lancet Psychiatry 2021;8:130‑40.
Del Rio C, Collins LF, Malani P. Long‑term health consequences
of COVID‑19. JAMA 2020;324:1723‑4.
Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I,
et al. Anxiety and depression in COVID‑19 survivors: Role
of inflammatory and clinical predictors. Brain Behav Immun
;89:594‑600.
Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE,
Spudich S. Neuropathogenesis and neurologic manifestations
of the coronaviruses in the age of coronavirus disease 2019:
A review. JAMA Neurol 2020;77:1018‑27.
Mendelson M, Nel J, Blumberg L, Madhi S, Dryden M,
Stevens W, et al. Long‑COVID: An evolving problem with an
extensive impact. S Afr Med J 2021;111:10‑2.
Guedj E, Campion J, Dudouet P, Kaphan E, Bregeon F,
Tissot‑Dupont H, et al. 18 F‑FDG brain PET hypometabolism
in patients with long COVID. Eur J Nucl Med Mol Imaging
;48:2823‑33.
Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ.
‑month neurological and psychiatric outcomes in 236 379
survivors of COVID‑19: A retrospective cohort study using
electronic health records. Lancet Psychiatry 2021;8:416‑27.
Heneka MT, Golenbock D, Latz E, Morgan D, Brown R.
Immediate and long‑term consequences of COVID‑19 infections
for the development of neurological disease. Alzheimer’s Res
Ther 2020;12:1‑3. doi: 10.1186/s13195‑020‑00640‑3.
Muccioli L, Pensato U, Cani I, Guarino M, Cortelli P, Bisulli F.
COVID‑19‑associated encephalopathy and cytokine‑mediated
neuroinflammation. Ann Neurol 2020;88:860‑1.
Pilotto A, Padovani A. Reply to the letter” COVID‑19‑associated
encephalopathy and cytokine‑mediated neuroinflammation”. Ann
Neurol 2020;88:861‑2.
South K, McCulloch L, McColl BW, Elkind MS, Allan SM,
Smith CJ. Preceding infection and risk of stroke: An old
concept revived by the COVID‑19 pandemic. Int J Stroke
;15:722‑32.
Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y,
Lucchinetti CF. Neuropathology of COVID‑19: A spectrum of
vascular and acute disseminated encephalomyelitis (ADEM)‑like
pathology. Acta Neuropathol 2020;140:1‑6.
Ameres M, Brandstetter S, Toncheva AA, Kabesch M, Leppert D,
Kuhle J, et al. Association of neuronal injury blood marker
neurofilament light chain with mild‑to‑moderate COVID‑19.
J Neurol 2020;267:3476‑8.
Bortolato B, F Carvalho A, K Soczynska J, I Perini G,
S McIntyre R. The involvement of TNF‑α in cognitive
dysfunction associated with major depressive disorder: An
opportunity for domain specific treatments. Curr Neuropharmacol
;13:558‑76.
Perrin R, Riste L, Hann M, Walther A, Mukherjee A, Heald A.
Into the looking glass: Post‑viral syndrome post COVID‑19. Med
Hypotheses 2020;144:110055. doi: 10.1016/j.mehy. 2020.110055.
Kaseda ET, Levine AJ. Post‑traumatic stress disorder:
A differential diagnostic consideration for COVID‑19 survivors.
Clin Neuropsychol 2020;34:1498‑514.
Miglis MG, Goodman BP, Chemali KR, Stiles L. Re: ‘Post‑COVID‑19 chronic symptoms’ by Davido et al. Clin
Microbiol Infect 2021;27:494.
Tian Y, Rong L, Nian W, He Y. gastrointestinal features in
COVID-19 and the possibility of faecal transmission. Aliment
Pharmacol Ther 2020;51:843‑51.
Schmulson M, Dávalos M, Berumen J. Beware: Gastrointestinal
symptoms can be a manifestation of COVID‑19. Rev
Gastroenterol Méx (Engl Ed) 2020;85:282‑7.
Rizvi A, Patel Z, Liu Y, Satapathy SK, Sultan K, Trindade AJ,
et al. Gastrointestinal sequelae 3 and 6 months after
hospitalization for coronavirus disease 2019. Clin Gastroenterol
Hepatol 2021;271‑81.
Weng J, Li Y, Li J, Shen L, Zhu L, Liang Y, et al. Gastrointestinal
sequelae 90 days after discharge for COVID‑19. Lancet
Gastroenterol Hepatol 2021;6:344‑6.
Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X, et al. Prolonged
presence of SARS‑CoV‑2 viral RNA in faecal samples. Lancet
Gastroenterol Hepatol 2020;5:434‑5.
Effenberger M, Grabherr F, Mayr L, Schwaerzler J, Nairz M,
Seifert M, et al. Faecal calprotectin indicates intestinal
inflammation in COVID‑19. Gut 2020;69:1543‑4.
Wang MK, Yue HY, Cai J, Zhai YJ, Peng JH, Hui JF, et al.
COVID‑19 and the digestive system: A comprehensive review.
World J Clin Cases 2021;9:3796‑813.
Cheung KS, Hung IFN, Chan PPY, Lung KC, Tso E, Liu R, et al.
Gastrointestinal manifestations of SARS‑CoV‑2 infection and
virus load in fecal samples from a Hong Kong cohort: Systematic
review and meta‑analysis. Gastroenterology 2020;159:81‑95.
Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for
Gastrointestinal Infection of SARS‑CoV‑2. Gastroenterology
;158:1831‑3.e3.
Donati Zeppa S, Agostini D, Piccoli G, Stocchi V, Sestili P.
Gut microbiota status in COVID‑19: An unrecognized player?
Front Cell Infect Microbiol 2020;10:576551. doi: 10.3389/fcimb.
576551.
Bradley KC, Finsterbusch K, Schnepf D, Crotta S, Llorian M,
Davidson S, et al. Microbiota‑driven tonic interferon signals in
lung stromal cells protect from influenza virus infection. Cell
Rep 2019;28:245‑56 e4.
McMahon DE, Gallman AE, Hruza GJ, Rosenbach M, Lipoff JB,
Desai SR, et al. Long COVID in the skin: A registry analysis
of COVID‑19 dermatological duration. Lancet Infect Dis
;21:313‑4.
Tammaro A, Parisella FR, Adebanjo GAR. Cutaneous long
COVID. J Cosmet Dermatol 2021;20:2378‑9.
Moreno-Arrones O, Lobato-Berezo A, Gomez-Zubiaur A,
Arias-Santiago S, Saceda-Corralo D, Bernardez-Guerra C, et al.
SARS-CoV-2-induced telogen effluvium: A multicentric study.
J Eur Acad Dermatol Venereol 2021;35:e181‑3.
Abrantes TF, Artounian KA, Falsey R, Simão JCL,
Vañó‑Galván S, Ferreira SB, et al. Time of onset and duration
of post‑COVID‑19 acute telogen effluvium. J Am Acad Dermatol
;85:975‑6.
Mehta P, Bunker CB, Ciurtin C, Porter JC, Chambers RC,
Papdopoulou C, et al. Chilblain‑like acral lesions in long
COVID‑19: Management and implications for understanding
microangiopathy. Lancet Infect Dis 2021;21:912. doi: 10.1016/
S1473‑3099(21)00133‑X.
Sykes DL, Holdsworth L, Jawad N, Gunasekera P,
Morice AH, Crooks MG. Post‑COVID‑19 symptom burden:
What is long‑COVID and how should we manage it? Lung
;199:113‑9.
Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F,
et al. Persistent fatigue following SARS‑CoV‑2 infection is
common and independent of severity of initial infection. Plos
One 2020;15:e0240784.
Office for National Statistics. UK Office for National
Statistics. Prevalence of long COVID symptoms and
COVID‑19 complications. Available from: https://www.ons.
gov.uk/peoplepopulationandcommunity/healthandsocialcare/
healthandlifeexpectancies/datasets/prevalenceoflongCOVID
symptomsandCOVID19complications.
Miyazato Y, Morioka S, Tsuzuki S, Akashi M, Osanai Y,
Tanaka K, et al., editors. Prolonged and late‑onset symptoms
of coronavirus disease 2019. Open Forum Infectious Diseases.
Oxford University Press US; 2020.
van den Borst B, Peters JB, Brink M, Schoon Y,
Bleeker‑Rovers CP, Schers H, et al. Comprehensive health
assessment 3 months after recovery from acute coronavirus
disease 2019 (COVID‑19). Clin Infect Dis 2021;73:e1089‑98.
Poyraz BÇ, Poyraz CA, Olgun Y, Gürel Ö, Alkan S,
Özdemir YE, et al. Psychiatric morbidity and protracted
symptoms after COVID‑19. Psychiatry Res 2021;295:113604.
doi: 10.1016/j.psychres. 2020.113604.
Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS,
Bowyer RC, et al. Attributes and predictors of Long‑COVID:
Analysis of COVID cases and their symptoms collected
by the COVID symptoms study app. medRxiv 2020. doi:
1101/2020.10.19.20214494.
Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Persistent
symptoms 1.5–6 months after COVID‑19 in non‑hospitalised
subjects: A population‑based cohort study. Thorax 2021;76:405‑7.
Taboada M, Cariñena A, Moreno E, Rodríguez N, Domínguez MJ,
Casal A, et al. Post‑COVID‑19 functional status six‑months after
hospitalization. J Infect 2021;82:e31‑3.
Raman B, Cassar MP, Tunnicliffe EM, Filippini N, Griffanti L,
Alfaro‑Almagro F, et al. Medium‑term effects of SARS‑CoV‑2
infection on multiple vital organs, exercise capacity, cognition,
quality of life and mental health, post‑hospital discharge.
EClinicalMedicine 2021;31:100683. doi: 10.1016/j.eclinm.
100683.
Hewitt J, Carter B, Vilches‑Moraga A, Quinn T, Braude P,
Verduri A. Th e effect of frailty on survival in patients with
COVID‑19 (COPE): A multicentre, European, observational
cohort study. Lancet Public Health 2020;5:e444‑51.
Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS,
et al. ‘Long‑COVID’: A cross‑sectional study of persisting
symptoms, biomarker and imaging abnormalities following
hospitalisation for COVID‑19. Thorax 2021;76:396‑8.
Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E,
Berry S, et al. Risk factors and disease profile of post‑vaccination
SARS‑CoV‑2 infection in UK users of the COVID Symptom
Study app: A prospective, community‑based, nested, case‑control
study. Lancet Infect Dis 2021;22:43‑55.
Ledford H. Do vaccines protect against long COVID? What the
data say. Nature 2021;599:546‑8.
Office for National Statistics. Coronavirus (COVID‑19)
vaccination and self‑reported long COVID in the UK:
October 2021. 2021. Available from: https://www.ons.
gov.uk/peoplepopulationandcommunity/healthandsocialcare/
conditionsanddiseases/articles/coronavirus COVID19vaccinationa
ndselfreportedlongCOVIDintheuk/25october2021.
Akrami A, Assaf G, Davis H, Harris K, Iwasaki A, Krumholz H,
et al. Change in symptoms and immune response in people
with post‑acute sequelae of SARS‑Cov‑2 infection (PASC)
after SARS‑Cov‑2 vaccination. medRxiv 2021. doi:
1101/2021.07.21.21260391.
Guideline N. NICE Guideline; COVID‑19 rapid guideline:
Managing the long‑term effects of COVID‑19. Available from:
https://www.nice.org.uk/guidance/ng188.
George PM, Barratt SL, Condliffe R, Desai SR, Devaraj A,
Forrest I, et al. Respiratory follow‑up of patients with COVID‑19
pneumonia. Thorax 2020;75:1009‑16.
Sivan M, Taylor S. NICE guideline on long COVID. BMJ
;371:m4938. doi: 10.1136/bmj.m4938.
Barker‑Davies RM, O’Sullivan O, Senaratne KPP, Baker P,
Cranley M, Dharm‑Datta S, et al. The Stanford Hall consensus
statement for post‑COVID‑19 rehabilitation. Br J Sports Med
;54:949‑59.
Wang TJ, Chau B, Lui M, Lam G‑T, Lin N, Humbert S. PM&R
and pulmonary rehabilitation for COVID‑19. Am J Phys Med
Rehabil 2020. doi: 10.1097/PHM.0000000000001505.
Grigoletto I, Cavalheri V, de Lima FF, Ramos EMC. Recovery
after COVID‑19: The potential role of pulmonary rehabilitation.
Braz J Phys Ther 2020;24:463‑4.
Liu K, Zhang W, Yang Y, Zhang J, Li Y, Chen Y. Respiratory
rehabilitation in elderly patients with COVID‑19: A randomized
controlled study. Complement Ther Clin Pract 2020;39:101166.
doi: 10.1016/j.ctcp. 2020.101166.
Demeco A, Marotta N, Barletta M, Pino I, Marinaro C, Petraroli A,
et al. Rehabilitation of patients post‑COVID‑19 infection:
A literature review. J Int Med Res 2020;48:0300060520948382.
doi: 10.1177/0300060520948382.
Fu Q, Levine BD. Exercise and non‑pharmacological treatment
of POTS. Auton Neurosci 2018;215:20‑7.
Larun L, Brurberg KG, Odgaard‑Jensen J, Price JR. Exercise
therapy for chronic fatigue syndrome. Cochrane Database Syst
Rev 2019;10:CD003200. doi: 10.1002/14651858.CD003200.
pub8.
Twisk F, Maes M. A review on cognitive behavorial
therapy (CBT) and graded exercise therapy (GET) in myalgic
encephalomyelitis (ME)/chronic fatigue syndrome (CFS): CBT/
GET is not only ineffective and not evidence‑based, but also
potentially harmful for many patients with ME/CFS. Neuro
Endocrinol Lett 2009;30:284‑99.
Torrisi SE, Kahn N, Vancheri C, Kreuter M. Evolution and
treatment of idiopathic pulmonary fibrosis. Presse Méd
;49:104025. doi: 10.1016/j.lpm. 2020.104025.
Raghu G, Wilson KC. COVID‑19 interstitial pneumonia:
Monitoring the clinical course in survivors. Lancet Respir Med
;8:839‑42.
Desai AD, Boursiquot BC, Melki L, Wan EY. Management
of arrhythmias associated with COVID‑19. Curr Cardiol Rep
;23:1‑9. doi: 10.1007/s11886‑020‑01434‑7.
Hendren NS, Drazner MH, Bozkurt B, Cooper Jr LT. Description
and proposed management of the acute COVID‑19 cardiovascular
syndrome. Circulation 2020;141:1903‑14.